ABUS News and Press, Arbutus Biopharma Corporation From 11/13/25

2025-11-13 08:04:56 ET More on Arbutus Biopharma Arbutus: IP Drama With High Stakes Seeking Alpha’s Quant Rating on Arbutus Biopharma Historical earnings data for Arbutus Biopharma Financial information for Arbutus Biopharma Read the full art...

WARMINSTER, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today reported third quarter 2025 financial results and provided a co...

Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as a Poster of Distinction WARMINSTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Arbu...

2025-09-15 16:27:30 ET Investment Thesis Arbutus Biopharma, headquartered in Warminster, Pennsylvania, is a clinical-stage biopharmaceutical company . Its main focus is on expertise in liposomal drug delivery and RNA interference. Arbutus owns a broad and diverse patent port...

Arbutus Biopharma Corporation (ABUS) is expected to report $-0.02 for Q2 2025

2025-08-06 07:43:02 ET More on Arbutus Biopharma Seeking Alpha’s Quant Rating on Arbutus Biopharma Historical earnings data for Arbutus Biopharma Financial information for Arbutus Biopharma Read the full article on Seeking Alpha For further det...

Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation of Anuj Hasija Dr. Harry Janssen joins the Arbutus Scientific Advisory Boar...

Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan Feld, Ed Gane, Anna Lok, Mark Sulkowski and Man-Fung Yuen join Arbutus Scientific Advisory Board WARMINSTER, Pa., June 25, 2025 (GLOBE NEWSWIRE) -- Arbut...

2025-06-04 02:00:00 ET Summary Tourlite Fund returned -4.6% in Q1 2025, underperforming the S&P 500, amid market volatility driven by Trump’s tariff agenda and macro uncertainty. We tactically increased net exposure during the quarter, favoring industrials and event-dri...

2025-05-31 00:20:00 ET Summary The equity portion of the Fund fell (gross of fees) and underperformed its benchmark, the NASDAQ Biotechnology Index. During the first quarter of 2025, we made several changes to the portfolio. With Donald Trump securing his second term, uncertai...